

Resource Summary Report

Generated by [RRID](#) on Aug 10, 2026

Anti-TOX-APC, human and mouse

RRID:AB_2654224

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-107-838, RRID:AB_2654224

Antibody Information

URL: http://antibodyregistry.org/AB_2654224

Proper Citation: Miltenyi Biotec Cat# 130-107-838, RRID:AB_2654224

Target Antigen: TOX

Host Organism: human

Clonality: monoclonal

Comments: Discontinued: 5-2018; Target Distribution T cells, thymocytes, T helper cells, liver, other; target type Non-CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-118-474. (RRID:AB_2751522).

Antibody Name: Anti-TOX-APC, human and mouse

Description: This monoclonal targets TOX

Target Organism: mouse, human

Clone ID: REA473

Antibody ID: AB_2654224

Vendor: Miltenyi Biotec

Catalog Number: 130-107-838

Record Creation Time: 20250819T211304+0000

Record Last Update: 20250819T221412+0000

Ratings and Alerts

No rating or validation information has been found for Anti-TOX-APC, human and mouse.

Warning: Discontinued: 2021

Discontinued: 5-2018; Target Distribution T cells, thymocytes, T helper cells, liver, other; target type Non-CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-118-474. (RRID:AB_2751522).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Kruglov O, et al. (2022) The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides. Cancer immunology, immunotherapy : CII, 71(4), 919.

Sekine T, et al. (2020) Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell, 183(1), 158.